AU2016295423B2 - Neuroprotective agents derived from spider venom peptides - Google Patents

Neuroprotective agents derived from spider venom peptides Download PDF

Info

Publication number
AU2016295423B2
AU2016295423B2 AU2016295423A AU2016295423A AU2016295423B2 AU 2016295423 B2 AU2016295423 B2 AU 2016295423B2 AU 2016295423 A AU2016295423 A AU 2016295423A AU 2016295423 A AU2016295423 A AU 2016295423A AU 2016295423 B2 AU2016295423 B2 AU 2016295423B2
Authority
AU
Australia
Prior art keywords
peptide
seq
cys
hila
asicla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016295423A
Other languages
English (en)
Other versions
AU2016295423A1 (en
Inventor
Irene CHASSAGNON
Claudia Ann IRELAND
Glenn Frederick KING
Sandy Steffany PINEDA GONZALEZ
Lachlan Douglas RASH
Robert Edward WIDDOP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Monash University
Original Assignee
University of Queensland UQ
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902845A external-priority patent/AU2015902845A0/en
Application filed by University of Queensland UQ, Monash University filed Critical University of Queensland UQ
Publication of AU2016295423A1 publication Critical patent/AU2016295423A1/en
Application granted granted Critical
Publication of AU2016295423B2 publication Critical patent/AU2016295423B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AU2016295423A 2015-07-17 2016-07-18 Neuroprotective agents derived from spider venom peptides Active AU2016295423B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015902845A AU2015902845A0 (en) 2015-07-17 ASIC1a modulators inspired by spider venom peptides
AU2015902845 2015-07-17
PCT/AU2016/050633 WO2017011863A1 (en) 2015-07-17 2016-07-18 Neuroprotective agents derived from spider venom peptides

Publications (2)

Publication Number Publication Date
AU2016295423A1 AU2016295423A1 (en) 2018-03-08
AU2016295423B2 true AU2016295423B2 (en) 2020-09-03

Family

ID=57833496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016295423A Active AU2016295423B2 (en) 2015-07-17 2016-07-18 Neuroprotective agents derived from spider venom peptides

Country Status (5)

Country Link
US (2) US10485847B2 (https=)
EP (1) EP3325503A4 (https=)
JP (1) JP6818215B2 (https=)
AU (1) AU2016295423B2 (https=)
WO (1) WO2017011863A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10485847B2 (en) 2015-07-17 2019-11-26 The University Of Queensland Neuroprotective agents derived from spider venom peptides
CA3057881A1 (en) 2017-04-04 2018-10-11 Baylor University Targeted mosquitocidal toxins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085931A2 (en) * 2000-05-10 2001-11-15 Centre National De La Recherche Scientifique-Cnrs- Polypeptide inhibiting a proton-gated na+ channel
WO2007030580A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
BRPI0605484A8 (pt) * 2006-11-21 2017-03-07 Fund Amparo Pesquisa Estado Minas Gerais Fapemig Toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto
NZ727213A (en) * 2012-03-09 2020-03-27 Vestaron Corp Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
US10485847B2 (en) 2015-07-17 2019-11-26 The University Of Queensland Neuroprotective agents derived from spider venom peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085931A2 (en) * 2000-05-10 2001-11-15 Centre National De La Recherche Scientifique-Cnrs- Polypeptide inhibiting a proton-gated na+ channel
WO2007030580A2 (en) * 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOHLEN, C. J. et al., "A Bivalent Tarantula Toxin Activates the Capsaicin Receptor, TRPV1, by Targeting the Outer Pore Domain", Cell, (2010), vol. 141, no. 5, pages 834 - 845 *
VASSILEVSKI, A. A. et al., "Novel class of spider toxin: Active principle from the Yellow Sac spider Cheiracanthium punctorium venom is a unique two-domain polypeptide", Journal of Biological Chemistry, (2010), vol. 285, pages 32293 - 32302 *

Also Published As

Publication number Publication date
US10485847B2 (en) 2019-11-26
US20200061156A1 (en) 2020-02-27
WO2017011863A1 (en) 2017-01-26
EP3325503A4 (en) 2019-03-27
US10881712B2 (en) 2021-01-05
EP3325503A1 (en) 2018-05-30
US20180207235A1 (en) 2018-07-26
JP2018522555A (ja) 2018-08-16
AU2016295423A1 (en) 2018-03-08
JP6818215B2 (ja) 2021-01-20

Similar Documents

Publication Publication Date Title
CA2628635C (en) Mu-conotoxin peptides and use thereof as a local anesthetic
EP2889308B1 (en) Alpha o-superfamily conotoxin peptide, pharmaceutical composition and use thereof
US20090088389A1 (en) Novel x-conotoxin peptides (-ii)
EP2504023A2 (en) Novel peptides isolated from spider venom, and uses thereof
EP2889307B1 (en) Alpha-conotoxin peptide, and medical composition and purpose thereof
JP2010509209A (ja) 新規なω−コノトキシン
US10881712B2 (en) Neuroprotective agents derived from spider venom peptides
WO2004099238A1 (en) NOVEL mu-CONOTOXIN PEPTIDES
CA2508129C (en) Novel x-conotoxin peptides (-i)
US8383162B2 (en) PHα1B toxin, CDNA of PHα1B toxin gene, pharmaceutical composition containing PHα1B toxin, process for their production and product
US7341998B2 (en) Conus californicus neurotoxins
Yan et al. A novel myotropic peptide from the skin secretions of the tree frog, Polypedates pingbianensis
NZ540582A (en) Chimaeric protein containing cysteine protease of liver fluke fused to hepatitis B core protein or ubiquitin, plants expressing said protein, and uses thereof as vaccine
US6767895B2 (en) I-superfamily conotoxins
WO2009035417A1 (en) Neuroprotective agents
HK1164340A (en) Chi-conotoxin peptides (ii)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)